What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

To determine if sCD126 can predict outcomes in patients with critical COVID-19 receiving tocilizumab.

April 29, 2026Journal of Innate Immunity0 citationsOpen Access

sCD126 as An Independent Prognostic Biomarker in Critical COVID-19

GMGiorgos MarinakisHellenic Red Cross EKEleni KarakikeNational and Kapodistrian University of Athens PKPanagiotis KoufargyrisNational and Kapodistrian University of Athens

Key Points

To determine if sCD126 can predict outcomes in patients with critical COVID-19 receiving tocilizumab.
Measured IL-6, soluble CD126, and sgp130 in 127 patients' serum within 24 hours of mechanical ventilation.
Conducted a prospective clinical study assessing biomarkers before tocilizumab treatment.
Used the World Health Organization Clinical Progression Scale by day 28 as the outcome measure.
sCD126 ≥100ng/ml independently associated with worse outcomes (Odds ratio 2.42).
Stepwise regression analysis indicated sCD126 as a significant predictor for WHO-CPS ≥6 by day 28.
Results highlight the potential of sCD126 as a prognostic biomarker in critical COVID-19.

Abstract

Introduction: Biomarkers to predict response of critical COVID-19 to tocilizumab (TCZ) are under investigation. Serum levels of interleukin (IL)-6 and IL-6 soluble receptors were studied in a cohort of patients all receiving treatment with TCZ. Methods: In this prospective clinical study, IL-6, soluble (s) CD126 and sgp130 were measured in the serum of 127 patients with critical COVID-19 the first 24 hours from start of mechanical ventilation and before start of TCZ treatment. Outcome was expressed as the World Health Organization Clinical Progression Scale (WHO-CPS) by day 28. The primary endpoint was the identification of a cut-off of the biomarkers which can predict WHO-CPS 6 or more by day 28. Results: Stepwise regression analysis with WHO-CPS ≥6 as the outcome and comorbidities, baseline oxygenation and baseline markers of severity showed that sCD126 ≥100ng/ml is independently associated with worse outcome (Odds ratio 2.42; 95% confidence intervals 1.05 to 5.63; p: 0.039). Conclusion: In a cohort of patients with critical COVID-19 receiving TCZ, sCD126 was a predictor of 28-day outcome.

问 AI

Bookmark

View Full Paper